JAK1 and mature T-cell and NK-cell non-Hodgkin lymphoma: Golidocitinib (AZD4205), a rationally-designed oral JAK1-specific inhibitor, was recently evaluated in a multinational phase 2 study (JACKPOT8) on R/R PTCL.